Xi Gu

36 Sanhao Street
Shenyang, 110004, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 42 publications

Correction: Association of human breast cancer CD44-/CD24- cells with delayed distant metastasis.

Correction: Association of human breast cancer CD44-/CD24- cells with delayed distant metastasis.

Journal: eLife

Published: September 10, 2025

Pitfalls in multinational sales data analysis.

Pitfalls in multinational sales data analysis.

Journal: The Lancet. Oncology

Published: July 16, 2025

Letter Re: A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial.

Letter Re: A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: March 31, 2025

Erratum to: FSIP1 enhances the therapeutic sensitivity to CDK4/6 inhibitors in triple-negative breast cancer patients by activating the Nanog pathway.

Erratum to: FSIP1 enhances the therapeutic sensitivity to CDK4/6 inhibitors in triple-negative breast cancer patients by activating the Nanog pathway.

Journal: Science China. Life sciences

Published: March 18, 2025

Neoadjuvant ARX788 plus pyrotinib versus trastuzumab, pertuzumab, docetaxel and carboplatin for HER2-positive breast cancer: a randomised phase 2b trial.

Neoadjuvant ARX788 plus pyrotinib versus trastuzumab, pertuzumab, docetaxel and carboplatin for HER2-positive breast cancer: a randomised phase 2b trial.

Journal: Nature communications

Published: February 19, 2025

Neoadjuvant chidamide combined with chemotherapy in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (MUKDEN 05): a multicentre, single-arm, phase 2 trial.

Neoadjuvant chidamide combined with chemotherapy in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (MUKDEN 05): a multicentre, single-arm, phase 2 trial.

Journal: The Lancet regional health. Western Pacific

Published: January 30, 2025

Advancements in liquid biopsy for breast Cancer: Molecular biomarkers and clinical applications.

Advancements in liquid biopsy for breast Cancer: Molecular biomarkers and clinical applications.

Journal: Cancer treatment reviews

Published: January 26, 2025

Unraveling the role and mechanism of mitochondria in postoperative cognitive dysfunction: a narrative review.

Unraveling the role and mechanism of mitochondria in postoperative cognitive dysfunction: a narrative review.

Journal: Journal of neuroinflammation

Published: September 25, 2024

RGS10 deficiency facilitates distant metastasis by inducing epithelial-mesenchymal transition in breast cancer.

RGS10 deficiency facilitates distant metastasis by inducing epithelial-mesenchymal transition in breast cancer.

Journal: eLife

Published: August 15, 2024

Correction: Advances in immunotherapy for triple-negative breast cancer.

Correction: Advances in immunotherapy for triple-negative breast cancer.

Journal: Molecular cancer

Published: September 14, 2023

Effects of neoadjuvant stereotactic body radiotherapy plus adebrelimab and chemotherapy for triple-negative breast cancer: A pilot study.

Effects of neoadjuvant stereotactic body radiotherapy plus adebrelimab and chemotherapy for triple-negative breast cancer: A pilot study.

Journal: eLife

Published: August 08, 2023

Neuroinflammation: The central enabler of postoperative cognitive dysfunction.

Neuroinflammation: The central enabler of postoperative cognitive dysfunction.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: July 25, 2023

Showing 1-12 of 42

Last Updated: 09/26/2026